

Rimke Oostvogels

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8928670/publications.pdf>

Version: 2024-02-01

16
papers

334
citations

1163117

8
h-index

1199594

12
g-index

16
all docs

16
docs citations

16
times ranked

969
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set. <i>Blood</i> , 2020, 136, 3033-3040.	1.4	146
2	Identification of minor histocompatibility antigens based on the 1000 Genomes Project. <i>Haematologica</i> , 2014, 99, 1854-1859.	3.5	43
3	Altered Peptide Ligands Revisited: Vaccine Design through Chemically Modified HLA-A2 Restricted T Cell Epitopes. <i>Journal of Immunology</i> , 2014, 193, 4803-4813.	0.8	40
4	Impact of etoposide and ASCT on survival among patients aged ≤ 65 years with stage II to IV PTCL: a population-based cohort study. <i>Blood</i> , 2022, 140, 1009-1019.	1.4	27
5	Efficacy of retreatment with immunomodulatory drugs and proteasome inhibitors following daratumumab monotherapy in relapsed and refractory multiple myeloma patients. <i>British Journal of Haematology</i> , 2018, 183, 60-67.	2.5	20
6	The diagnostic value of history and physical examination for COPD in suspected or known cases: a systematic review. <i>Family Practice</i> , 2009, 26, 260-268.	1.9	18
7	T Cells Specific for an Unconventional Natural Antigen Fail to Recognize Leukemic Cells. <i>Cancer Immunology Research</i> , 2019, 7, 797-804.	3.4	15
8	Systemic vasculitis in myelodysplastic syndromes. <i>Netherlands Journal of Medicine</i> , 2012, 70, 63-8.	0.5	12
9	The importance of the osmolality gap in ethylene glycol intoxication. <i>BMJ</i> , The, 2013, 347, f6904-f6904.	6.0	5
10	Characterization and modulation of anti- $\hat{1}^2$ TCR antibodies and their respective binding sites at the $\hat{1}^2$ TCR chain to enrich engineered T \hat{A} cells. <i>Molecular Therapy - Methods and Clinical Development</i> , 2021, 22, 388-400.	4.1	4
11	Adding Help to an HLA-A*24:02 Tumor-Reactive $\hat{1}^3$ TCR Increases Tumor Control. <i>Frontiers in Immunology</i> , 2021, 12, 752699.	4.8	2
12	Differences and Similarities in Treatment Paradigms and Goals between AL Amyloidosis and Multiple Myeloma. <i>Hemato</i> , 2021, 2, 680-691.	0.6	1
13	First-Line Treatment and Survival of Stage I(E) Peripheral T-Cell Lymphoma in the Netherlands; A Nationwide Population-Based Cohort Study. <i>Blood</i> , 2021, 138, 1381-1381.	1.4	1
14	Identification of New Hematopoietic Minor Histocompatibility Antigen UTA2-1; Ready for Application in Antitumor Immunotherapy. <i>Blood</i> , 2011, 118, 2979-2979.	1.4	0
15	Improved Vaccine Design For Adoptive Immunotherapy In Hematological Malignancies Through Chemically Modified Minor Histocompatibility Antigen Epitopes. <i>Blood</i> , 2013, 122, 5435-5435.	1.4	0
16	Identification of Minor Histocompatibility Antigens Based on the 1000 Genomes Project for Application in Therapeutic Dendritic Cell Vaccination. <i>Blood</i> , 2014, 124, 2418-2418.	1.4	0